How does a fractional CRO build pipeline for a medical device company in 2027?

What this looks like next to the common alternatives

The instinct at most device companies under $5M ARR is to solve pipeline with headcount: hire a VP of Sales, give them a territory, wait. That works in a market where the buyer is one person with a budget. It does not work when the purchase decision routes through a value analysis committee, an infection prevention review, a capital equipment queue that meets quarterly, and a procurement office bound by an existing GPO contract. The fractional CRO exists because the *process design* problem is separable from the *territory coverage* problem, and the process design problem is the one killing you first.

Set the realistic alternatives side by side.

Founder-led sales, continued. The founder has the surgeon relationships and the clinical fluency. That gets a device to first-in-human, first commercial case, maybe first three reference accounts. What it does not produce is a written qualification standard, a documented buying-committee map, or a CRM that anyone else could pick up. Founder-led sales fails not on effort but on transferability — every deal lives in one person's head, and the company cannot forecast, cannot delegate, and cannot survive that person spending four days a week in operating rooms instead of raising the next round.

A full-time VP of Sales. Fully loaded, a device VP with hospital-system credibility runs well into the mid-six figures once you add base, variable, travel, and equity. The ramp is real: three to six months before they know your device, your regulatory posture, your reimbursement pathway, and your existing relationships well enough to be additive. If the go-to-market hypothesis turns out wrong — wrong call point, wrong channel, wrong price band — you discover it at month eight and unwinding it costs severance plus a re-search. That's a defensible bet at $5M+ ARR with a cleared, reimbursed, launch-ready device. It is an expensive way to learn at pre-revenue.

A contract clinical specialist or 1099 rep. Cheaper, faster, genuinely useful — a specialist who can scrub in, run a demo, and support a case is often the single highest-leverage hire for a device company with early traction. But a specialist executes inside a process; they do not build one. Ask a clinical specialist to design a tiered account strategy and negotiate a distributor commission structure and you have miscast the role.

An agency or outsourced SDR shop. These can work in SaaS where the call point is reachable by email and the qualification bar is a demo. In devices, a generic SDR firm burns your name with the exact 300 surgeons you needed. The email that says "quick 15 minutes to show you our innovative solution" is worse than no email — it marks the company as one that doesn't understand the room.

The fractional CRO. Eight to fifteen days a month, six-to-twelve-month engagement, terminable on short notice. The value is not hours; it's pattern recognition from having run this exact motion before — knowing that a Class II device with an established CPT code has a fundamentally different path than a Class III device carrying a de novo pathway and a payer coverage gap. That distinction alone reroutes an entire go-to-market plan, and a generalist RevOps leader from B2B software will not make it.

The honest trade-off: a fractional CRO is not in the building. They will not be in the hallway when the founder needs a gut check on pricing at 6pm. Fractional works when the company can absorb asynchronous leadership and has at least one internal person who can execute between sessions. If nobody executes between sessions, you have bought a very expensive strategy deck.

How to choose between them without guessing

Stage-gate the decision instead of debating it. Three variables carry almost all the weight: regulatory status, reimbursement clarity, and whether a repeatable process already exists.

Regulatory status. Pre-clearance, there is no pipeline in the commercial sense — there is relationship groundwork. A fractional CRO is still useful here, but the deliverable is a KOL map, a conference calendar, an evidence-generation plan, and a pre-launch target list. Paying for a full-time VP to build a pipeline they legally cannot close is a common and expensive error. Post-clearance with a reimbursement pathway, the commercial motion turns on and the fractional CRO's job shifts to conversion mechanics.

Reimbursement clarity. If the hospital cannot get paid, the surgeon's enthusiasm is irrelevant — the value analysis committee will kill it on economics. Ask any candidate how they'd handle a device that works clinically but lands in a coding gray zone. A strong answer talks about a Category III code pathway, hospital cost-offset modeling, or a risk-sharing pilot structure. A weak answer talks about "getting in front of more surgeons."

Process maturity. Score yourself honestly on five things: Is there a written definition of a qualified opportunity? Is the buying committee documented per account? Is there a CRM that reflects reality? Is there a loss-reason taxonomy? Can a new rep read a playbook and run a first call? Two or fewer yeses means you have a process problem, and process problems are what fractional leadership is actually good at.

One more filter worth applying: the founder's own willingness to let go. Fractional CRO engagements at device companies fail more often on founder control than on CRO capability. If the founder will not hand over the surgeon relationships, will not let a call get recorded, will not accept a qualification standard that disqualifies their favorite prospect — the engagement produces friction and a deck. Interview yourself as hard as you interview the candidate.

Finally, weigh geography. Many experienced device revenue leaders cluster around Minneapolis, Boston, the Bay Area, and Southern California, because that's where the device industry concentrated. A fractional arrangement lets you access that network without relocating anyone, which is a real and underrated advantage over a full-time search constrained to your metro.

Costs, timelines, and what impact actually looks like

Price the engagement in days, not in outcomes, because outcome-priced device engagements create incentives to chase the wrong things. A typical structure is a monthly retainer covering a defined number of days — often eight to fifteen — with an explicit scope, plus a variable component tied to pipeline milestones rather than closed revenue. When variable comp is tied to closed-won in a market with 6–18 month cycles, you have built a compensation plan that pays nothing for four quarters and then pays on deals the CRO may have had little to do with. Milestone-based variable comp is the cleaner instrument: a defined bonus when ten qualified evaluations are created, when the first GPO application is submitted, when the first distributor agreement is signed, when the first reference case study is published.

Equity is rare and should stay rare. A small equity component in lieu of higher cash can make sense at true pre-revenue, but for a company with commercial traction, cash keeps the relationship clean and terminable — which is the entire point of going fractional.

Now the timeline, which is where expectations get set badly.

Days 1–30 — forensics. The CRO reads the last twelve months of the CRM, not as a report but as an archaeological dig: stage distribution, opportunity age, deals that should have been killed six months ago, the loss reasons nobody wrote down. They pull pipeline velocity in Salesforce or HubSpot, and if the company runs conversation intelligence like Gong or Clari, they listen to stalled deals rather than won ones — losses are where the process defect lives. Parallel to that: structured interviews with the founder and clinical team. Which surgeons have already been approached? What objections came back? Are there existing IDN or GPO relationships nobody documented? This is a forensic examination of past activity, not a discovery call.

Days 30–60 — architecture. Target account list narrowed to 20–30 hospitals or surgical groups, tiered by procedure volume, existing vendor entrenchment, and reimbursement fit. Tier 1 gets founder-or-CRO direct outreach. Tier 2 gets a sequenced multichannel campaign through a tool like Outreach or Salesloft. Tier 3 gets educational nurture and nothing more. The qualification standard gets written down. The buying-committee map gets built per Tier 1 account — surgeon champion, department chief, value analysis chair, procurement, infection prevention, finance, and increasingly a clinical informatics stakeholder if the device generates data.

Days 60–90 — first motion. Outreach live, first surgeon meetings booked, conference calendar locked. Expect first qualified conversations in weeks two to four *if* clinical evidence and a target list already exist. If evidence has to be generated first, honest timelines stretch to three to six months before outbound makes any sense at all, and a CRO who promises otherwise is selling.

Months 3–12 — compounding. GPO applications with organizations like Vizient, Premier, or HealthTrust run long — six to twelve months is a normal cycle, and the application is a project, not an email. Distributor agreements negotiate faster but require training investment; regional distributors typically want a meaningful share of selling price, and the number is negotiable against exclusivity, territory, and who carries inventory risk. First procedure to reference case study is another quarter minimum, because you need outcomes data and a surgeon willing to attach their name to it.

Measure leading indicators, and only leading indicators, in the first two quarters: qualified opportunities where a formal evaluation or trial has been agreed to; surgeon meetings with someone who can actually influence purchase; weighted pipeline value; and conversion rate from first contact to product evaluation. That last one is the diagnostic — if outreach volume is fine but evaluation conversion is flat, the problem is the clinical evidence package, not the sequencing.

The adjacent lesson worth stealing: this is the same measurement discipline that RevOps teams apply in any long-cycle enterprise motion — regulated fintech, industrial capital equipment, clinical software. Long cycles force you to instrument the middle of the funnel because the end of the funnel reports too late to steer by.

Implementation, handoff, and the machinery underneath

The engagement produces artifacts or it produced nothing. Insist on a defined deliverable set: a written qualification standard, a tiered account plan with named committee members, a CRM configured to the actual stage gates of a device sale (not the default SaaS pipeline), a loss-reason taxonomy, a distributor or GPO channel plan, and a content and evidence roadmap. Every one of those survives the CRO's departure. A weekly forecast call and a set of slides do not.

Pipeline generation in devices runs on evidence, so the CRO's content mandate is specific and unglamorous. White papers or early case reports summarizing outcomes. Video testimonials from early-adopter surgeons, often captured at conferences because that is the only place they hold still. Reimbursement guides written for hospital finance, not for surgeons — a different document with different math. And where budget and timeline allow, peer-reviewed publication, which remains the single highest-trust asset in the category and cannot be shortcut. Distribution runs through specialty-targeted LinkedIn campaigns, procurement-facing email programs, and booth collateral timed to the conference calendar — AAOS, ACC, RSNA and their specialty equivalents. The CRO works backward from those dates: pre-event outreach cadence, in-booth meeting scheduling, post-event data package within a week while memory is fresh.

Key opinion leader relationships get contracted, not assumed. A KOL who will speak at a session or host a webinar generates qualified interest at a rate cold outreach cannot approach, and the arrangement should be a documented consulting agreement with clear scope — this is a regulated space, and sunshine-act reporting and compliance review are not optional. Any fractional CRO who waves off compliance on KOL payments is a liability, not an asset.

Data access has to be real on day one: read access to the CRM, to conversation intelligence if it exists, to historical email threads, and to the regulatory and reimbursement documentation. A CRO working from summaries produces summary-grade advice.

Plan the handoff from month one. Name the internal person who will own the process when the engagement ends — a chief of staff, a commercial ops manager, a founder-designate. That person attends every working session. The exit criteria should be written into the agreement: process documented, first cohort of reference accounts live, channel agreements signed or clearly dead, and a named internal owner running weekly pipeline review without the CRO in the room. A well-run engagement often tapers — fifteen days a month down to eight, down to four days of advisory — rather than ending on a cliff.

The failure modes are consistent enough to name. Founder won't release relationships. No internal executor, so nothing moves between sessions. Variable comp tied to closed revenue in an 18-month cycle. A generalist hired on price who applies MEDDIC or BANT to a value analysis committee and wonders why nothing advances. And the quiet one: no defined end state, so the retainer becomes a subscription and nobody ever asks whether the process it was supposed to build exists.

Related questions

Can a fractional CRO help before FDA clearance?

Yes, with a different mandate. Pre-clearance work is KOL mapping, conference strategy, evidence planning, and pre-launch target list construction. No revenue is generated, so measure the engagement on relationship depth and launch readiness rather than pipeline dollars.

How is this different from a fractional CRO for a SaaS company?

The call point, the buying committee, and the evidence standard. SaaS sells to a budget owner on ROI; devices sell to a clinical champion who must then survive a value analysis committee on safety, outcomes, and hospital economics. A SaaS-only background usually does not transfer.

What does a distributor partnership actually change?

It trades margin for reach. A regional distributor already calls on procurement and can carry your device in an existing catalog, which shortens access dramatically — but you give up a share of selling price and control of the customer relationship, and you must invest real time training their reps on clinical value.

Should the fractional CRO own the CRM build?

They should own the design; someone else should own the build. The CRO defines stage gates, qualification criteria, and required fields that match a device sales cycle. Implementation belongs to a RevOps contractor or internal admin — CRO days are too expensive for configuration work.

What if we already have a full-time VP of Sales?

Then the fractional role is narrower and usually shorter: a channel strategy sprint, a pipeline diagnostic, or a GPO access project. Overlapping a fractional CRO on top of a full-time VP without a scope boundary creates authority confusion and usually ends badly for both.

FAQ

How quickly can a fractional CRO generate the first qualified lead?

Two to four weeks when clinical evidence and a target account list already exist — the CRO is sequencing existing assets. If evidence must be generated or clearance is pending, expect three to six months before outbound activity is even appropriate. Anyone promising qualified device opportunities in week one is describing a meeting, not an opportunity.

Should variable compensation be tied to closed revenue?

No. With 6–18 month cycles, revenue-tied variable comp pays nothing for a year and then pays on deals whose origin is ambiguous. Tie variable comp to pipeline milestones: qualified evaluations created, GPO application submitted, distributor agreement signed, first reference case published. Those are measurable within the engagement window.

Do fractional CROs need to be local to us?

No, but they should travel to two to four major conferences per year, come onsite for initial onboarding, and attend quarterly reviews in person. The rest is workable remotely. Many experienced device revenue leaders sit in Minneapolis, Boston, or Southern California and bring regional networks with them.

How many days per month is right?

Eight to fifteen for a build engagement, tapering as the process stabilizes. Below eight days, momentum dies between sessions. Above fifteen, you are paying fractional rates for something approaching full-time coverage and should price a real hire. Scope the days against defined deliverables, not against a feeling of access.

What signals a bad fit during the interview?

A candidate who cannot distinguish a Class II device with an established code from a Class III on a de novo pathway. One who describes hospital selling as "getting in front of surgeons" without mentioning value analysis or reimbursement. One who waives off compliance around KOL agreements. And one who promises booked revenue in the first quarter.

When should the engagement end?

When the exit criteria written at the start are met: process documented, reference accounts live, channel agreements resolved either way, and a named internal owner running weekly pipeline review unaided. If those criteria were never written down, the honest answer is that nobody knows — which is itself the reason to write them down.

Sources

• U.S. Food and Drug Administration — Device Classification
• FDA — 510(k) Premarket Notification
• Centers for Medicare & Medicaid Services
• AdvaMed — Advanced Medical Technology Association
• Vizient
• Premier Inc.
• American Academy of Orthopaedic Surgeons
• Radiological Society of North America
• Harvard Business Review
• CMS Open Payments

Related on PULSE

• What should an SMB company look for in a fractional CRO in 2027?
• Is there a fractional CRO available near me in Boise in 2027?
• Is there a fractional CRO available near me in Massachusetts in 2027?
• Is there a fractional CRO available near me in Pasadena in 2027?
• Is there a fractional Chief Revenue Officer available near me in Detroit in 2027?
• Who is the best fractional Chief Revenue Officer in Middletown in 2027?